JP2011519869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519869A5 JP2011519869A5 JP2011507708A JP2011507708A JP2011519869A5 JP 2011519869 A5 JP2011519869 A5 JP 2011519869A5 JP 2011507708 A JP2011507708 A JP 2011507708A JP 2011507708 A JP2011507708 A JP 2011507708A JP 2011519869 A5 JP2011519869 A5 JP 2011519869A5
- Authority
- JP
- Japan
- Prior art keywords
- antigens
- cells
- composition
- cell
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 71
- 102000036639 antigens Human genes 0.000 claims description 71
- 108091007433 antigens Proteins 0.000 claims description 71
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 33
- 239000002671 adjuvant Substances 0.000 claims description 32
- 210000002865 immune cell Anatomy 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 108010029697 CD40 Ligand Proteins 0.000 claims description 8
- 102100032937 CD40 ligand Human genes 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 6
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 6
- 108091061960 Naked DNA Proteins 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 4
- 239000011824 nuclear material Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000029662 T-helper 1 type immune response Effects 0.000 claims description 2
- -1 antibodies Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4999008P | 2008-05-02 | 2008-05-02 | |
| US61/049,990 | 2008-05-02 | ||
| US5029408P | 2008-05-05 | 2008-05-05 | |
| US61/050,294 | 2008-05-05 | ||
| PCT/US2009/042673 WO2009135199A2 (en) | 2008-05-02 | 2009-05-04 | Vaccine compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014035409A Division JP2014098035A (ja) | 2008-05-02 | 2014-02-26 | ワクチン組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011519869A JP2011519869A (ja) | 2011-07-14 |
| JP2011519869A5 true JP2011519869A5 (enExample) | 2013-05-16 |
| JP5709264B2 JP5709264B2 (ja) | 2015-04-30 |
Family
ID=41255892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507708A Active JP5709264B2 (ja) | 2008-05-02 | 2009-05-04 | ワクチン組成物および方法 |
| JP2014035409A Withdrawn JP2014098035A (ja) | 2008-05-02 | 2014-02-26 | ワクチン組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014035409A Withdrawn JP2014098035A (ja) | 2008-05-02 | 2014-02-26 | ワクチン組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20120128656A1 (enExample) |
| EP (1) | EP2285405A4 (enExample) |
| JP (2) | JP5709264B2 (enExample) |
| KR (1) | KR101689210B1 (enExample) |
| CN (2) | CN102076359A (enExample) |
| AU (1) | AU2009242471B2 (enExample) |
| CA (1) | CA2726007C (enExample) |
| IL (1) | IL209027A (enExample) |
| WO (1) | WO2009135199A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| KR102117350B1 (ko) * | 2010-04-13 | 2020-06-02 | 이뮤노베이티브 테라피스, 엘티디. | 조절 t 세포들의 저해를 위한 방법 및 조성물 |
| BR112013028285A2 (pt) * | 2011-05-03 | 2017-01-10 | Immunovative Therapies Ltd | indução de il-12 usando imunoterapia |
| CN104415335A (zh) * | 2013-09-02 | 2015-03-18 | 北京中康万达医药科技有限公司 | 体内个体化系统免疫治疗方法和装置 |
| US10272143B2 (en) | 2014-01-08 | 2019-04-30 | Immunovative Therapies Ltd. | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
| CN103911341B (zh) * | 2014-01-26 | 2016-04-13 | 山东迪博生物科技股份有限公司 | Th1细胞亚群的制备方法及其在制备抗肿瘤细胞制剂中的应用 |
| CN104630145A (zh) * | 2015-01-12 | 2015-05-20 | 杨世成 | 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物 |
| CN104830794A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于hpve7抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
| AU2017233035B2 (en) * | 2016-03-16 | 2021-08-05 | Neximmune, Inc. | Production of antigen-specific T-cells |
| KR20170127324A (ko) * | 2016-05-11 | 2017-11-21 | (주)제이티 | 반도체소자 캐리어, 이의 제조방법 및 이를 포함하는 소자핸들러 |
| IL300809A (en) * | 2020-09-02 | 2023-04-01 | Yztherapeutic Performance Ltd | Cellular preparation for the treatment of diseases and method of use |
| CA3243354A1 (en) * | 2022-02-03 | 2023-08-10 | Microvax Llc | A mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASES |
| CN117653720A (zh) * | 2023-11-28 | 2024-03-08 | 苏州尔生生物医药有限公司 | 一种抗原组分的提取方法及包含其的递送粒子和应用 |
| US20250319132A1 (en) * | 2024-04-16 | 2025-10-16 | Mirror Biologics, Inc. | Methods and compositions for improving the immune response against viral pathogens |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747024A (en) * | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
| US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
| US6797480B1 (en) | 1998-10-05 | 2004-09-28 | University Of Connecticut Health Center | Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents |
| US6875849B2 (en) * | 2001-05-01 | 2005-04-05 | Arizona Board Of Regents Of Behalf Of The University Of Arizona | Methods of recovering chaperone proteins and complexes thereof |
| US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| US20040202663A1 (en) * | 2003-01-28 | 2004-10-14 | Shanghai Sunway Biotech Co., Ltd. | Therapy for primary and metastatic cancers |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US7678572B2 (en) | 2004-02-26 | 2010-03-16 | Immunovative Therapies, Ltd. | Methods for preparing T-cells for cell therapy |
| EP1896570A2 (en) * | 2005-05-10 | 2008-03-12 | Avaris AB | Cellular vaccine and use thereof |
| US7553661B2 (en) * | 2005-05-31 | 2009-06-30 | Mcgill University | Stromal antigen-presenting cells and use thereof |
| DK2003978T3 (da) * | 2006-04-13 | 2014-07-07 | Immunovative Therapies Ltd | Allogen celleterapi til behandling af opportunistisk infektion |
| EP2091334A4 (en) * | 2006-10-31 | 2010-02-03 | Hasumi Internat Res Foundation | TUMOR TREATMENT BY INJECTION OF DENDRITIC CELLS AND CORRESPONDING VACCINE |
-
2009
- 2009-05-01 US US12/434,168 patent/US20120128656A1/en not_active Abandoned
- 2009-05-04 CN CN2009801254981A patent/CN102076359A/zh active Pending
- 2009-05-04 WO PCT/US2009/042673 patent/WO2009135199A2/en not_active Ceased
- 2009-05-04 AU AU2009242471A patent/AU2009242471B2/en active Active
- 2009-05-04 KR KR1020107027043A patent/KR101689210B1/ko active Active
- 2009-05-04 CA CA2726007A patent/CA2726007C/en active Active
- 2009-05-04 CN CN201810586541.5A patent/CN108743937B/zh active Active
- 2009-05-04 EP EP09740001A patent/EP2285405A4/en not_active Ceased
- 2009-05-04 JP JP2011507708A patent/JP5709264B2/ja active Active
-
2010
- 2010-10-31 IL IL209027A patent/IL209027A/en active IP Right Grant
-
2014
- 2014-02-26 JP JP2014035409A patent/JP2014098035A/ja not_active Withdrawn
-
2018
- 2018-12-10 US US16/215,116 patent/US10751372B2/en active Active
-
2020
- 2020-04-29 US US16/862,069 patent/US12233091B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519869A5 (enExample) | ||
| Lin et al. | Biomimetic nanomedicine-triggered in situ vaccination for innate and adaptive immunity activations for bacterial osteomyelitis treatment | |
| Lee et al. | Dendritic cell vaccines: a shift from conventional approach to new generations | |
| Morse et al. | Vaccine therapies for cancer: then and now | |
| Caldeira et al. | Virus-like particles as an immunogenic platform for cancer vaccines | |
| Jafari et al. | Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms | |
| Lu et al. | Development of foot-and-mouth disease vaccines in recent years | |
| JP2009506762A5 (enExample) | ||
| US20170080064A1 (en) | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio | |
| WO2004084939A8 (en) | Hiv-peptide-carrier-conjugates | |
| JP2017524337A5 (enExample) | ||
| ATE489969T1 (de) | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung | |
| JP2017525336A5 (enExample) | ||
| Chakravarty et al. | Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: its implication in designing a vaccination strategy | |
| Chuang et al. | Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+ CD25+ T regulatory cells | |
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| AU2006288348A1 (en) | Method for activation treatment of antigen-presenting cell | |
| IL161146A0 (en) | Antigen arrays for treatment of bone disease | |
| Groeneveldt et al. | Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy | |
| Britsch et al. | Applications of anti-cytomegalovirus T cells for cancer (Immuno) therapy | |
| Jia et al. | The future of cancer vaccines against colorectal cancer | |
| Ly | Progress toward the development of Lassa vaccines | |
| CN101090633A (zh) | 树突细胞肿瘤注射（dcti）疗法 | |
| Oli et al. | Vaccine types and reverse vaccinology | |
| Geng et al. | Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells |